Structure Therapeutics Inc.

GPCR · Nasdaq · SIC 2834: Pharmaceutical Preparations
54
SEC Filings

Business Summary

PART I . Overview We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). These important receptors regulate numerous and diverse physiological and patholo...

Next Earnings

Q2 FY2026 — expected 2026-08-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionGPCRdiscussed_in_filing Cybersecurity
topic_mentionGPCRdiscussed_in_filing Trusted Computing
topic_mentionGPCRdiscussed_in_filing Blockchain & Crypto
topic_mentionGPCRdiscussed_in_filing Capital Expenditure
topic_mentionGPCRdiscussed_in_filing Regulation
topic_mentionGPCRdiscussed_in_filing Healthcare & Bio
topic_mentionGPCRdiscussed_in_filing Platform & Ecosystem
topic_mentionGPCRdiscussed_in_filing Sovereign & Government
topic_mentionGPCRdiscussed_in_filing Cybersecurity
topic_mentionGPCRdiscussed_in_filing Trusted Computing
topic_mentionGPCRdiscussed_in_filing Blockchain & Crypto
topic_mentionGPCRdiscussed_in_filing Capital Expenditure
topic_mentionGPCRdiscussed_in_filing Regulation
topic_mentionGPCRdiscussed_in_filing Healthcare & Bio
topic_mentionGPCRdiscussed_in_filing Platform & Ecosystem
topic_mentionGPCRdiscussed_in_filing Sovereign & Government
topic_mentionGPCRdiscussed_in_filing Cybersecurity
topic_mentionGPCRdiscussed_in_filing Trusted Computing
topic_mentionGPCRdiscussed_in_filing Blockchain & Crypto
topic_mentionGPCRdiscussed_in_filing Capital Expenditure

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001104659-26-020562EDGAR127K words
2025-02-272024-12-310001558370-25-001826EDGAR
2024-03-082023-12-310001558370-24-002791EDGAR
2023-03-302022-12-310001558370-23-005141EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001104659-25-107829EDGAR81K words
2025-08-062025-06-300001558370-25-010541EDGAR
2025-05-082025-03-310001558370-25-006989EDGAR
2024-11-132024-09-300001558370-24-015531EDGAR
2024-08-082024-06-300001558370-24-011616EDGAR
2024-05-092024-03-310001558370-24-007642EDGAR
2023-11-172023-09-300001558370-23-019203EDGAR
2023-08-102023-06-300001558370-23-014524EDGAR
2023-05-112023-03-310001558370-23-009425EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-160001104659-26-028023EDGAR2K words
2026-02-260001104659-26-020494EDGAR
2026-01-050001104659-26-000620EDGAR
2025-12-100001104659-25-120015EDGAR
2025-12-080001104659-25-119095EDGAR
2025-11-060001104659-25-107740EDGAR
2025-08-060001104659-25-074712EDGAR
2025-06-250001104659-25-062576EDGAR
2025-05-080001104659-25-046149EDGAR
2025-02-270001104659-25-018275EDGAR

54 total filings indexed. 31 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001888886
TickerGPCR
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedE9

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 68b6cb03220e89a0d388854a22f197795dadf176bc515d658462ab8bea36a83a
parent: 8277fa3e1202721a9865d30dc95860442b5f97e1f331524469e83b94c52fdfbd
content hash: 3e0fffbdbf9bfacdff48573635e5fb7ede627cbcca3f213bf16e01e3636a6f70
signed: 2026-04-13T04:45:21.058Z
sources: 13 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf